Demant A/S (WILYY)
Valor JustoFundamental
48
Precio
$945.00
Capitalización Bursátil
$37.43B
Parte 1 · Cuánto vale la empresa
Resumen
Demant is a Danish hearing healthcare group that designs and manufactures hearing aids sold under brands including Oticon and Bernafon, and runs a network of owned and franchised clinics where audiologists test patients' hearing and fit them with a device. A smaller unit sells diagnostic equipment, such as audiometers and balance-testing systems, to clinics and hospitals. It sold a separate communications business, which made headsets and speakerphones, and has treated it as a discontinued operation since 2024.
Cómo genera ingresos
Most revenue comes from selling hearing aids, physical devices fitted to a patient's ear that are typically replaced every several years, plus recurring sales of batteries, accessories, repairs and clinical services around them. A smaller stream comes from selling diagnostic equipment to clinics and hospitals. Because hearing loss is a chronic, progressive condition, each patient tends to return to buy a replacement device or accessories over time, and purchases are often reimbursed or subsidized by public healthcare systems in Demant's main markets.
Qué impulsa la demanda
DefensivoHearing loss is mainly a consequence of aging, so the number of people who need a hearing aid grows steadily with an older population and is not closely tied to how the economy is doing in a given year. Purchases can still be postponed for a few months by a household under financial strain, but the underlying medical need does not disappear the way demand for a discretionary product would in a downturn.
Los argumentos a favor
Buyers argue that an aging population in Demant's main markets keeps the number of potential hearing aid users growing for decades to come, and that 2025's revenue growth shows the underlying demand for its devices and clinics remaining solid.
Los argumentos en contra
Sellers worry that 2025's profit fell even as revenue grew, forcing the company into a cost-cutting programme, and that pricing and reimbursement pressure in a market with several well-capitalized rivals could keep squeezing margins even if the number of patients keeps rising.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$3.74B
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Beneficio Neto
$245M
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Flujo de Caja Libre
-
Patrimonio Neto Total
$24.56B
Pasivo Total
$426M
Ratio de Liquidez
1.63
Cobertura de Intereses
-
Deuda/EBITDA
2.60
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$877.74
Precio Actual
$945.00
Margen de Seguridad
-7.7%
Rango de Valor Justo
$570.53 - $1184.95
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
123.23
ROE
2.7%
Ratio P/B
17.52
P/FCF
-
Margen Bruto
76.3%
ROIC
0.5%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
0.5%
WACC
8.1%
ROIC − WACC
-7.6 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (10)
- Price CAGR 14.61%
- Gross Margin 76.3%
- Debt/Equity ratio
- Operating Margin 15.8%
- Current Ratio
- Debt/EBITDA
- ROE 15.3%
- Revenue Growth 5Y 9.7%
- Analyst Consensus 50% Buy
- Net Margin Trend 53.0% vs 43.8%
Fallido (8)
- ROIC 0.5%
- P/B Ratio 17.52
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Surprise avg -7.5%
- PEG Ratio 4.21
- Earnings Quality (OCF/NI) 0.29
- Piotroski F-Score 1/9
No disponible (9)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
No hay declaraciones institucionales para esta empresa.
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Thomas Wilhelmsen | Group Chief Executive Officer | 51 |
| Mr. Christian Berg | Group Chief Financial Officer | 56 |
| Mr. Bjorge Grimholt | Executive Vice President of Maritime Services | - |
| Ms. Benedicte Teigen Gude | Chief of Staff | - |
| Mr. Geir Flaesen | Executive Vice President of New Energy | - |
| Mr. Carl Schou | President & CEO of Wilhelmsen Ship Management (WSM) | - |
| Mr. John Egil Stangeland | Chief Executive Officer of NorSea Group | - |
| Mr. Age Sturtzel Holm | Vice President of Investor Relations & Corporate Support | - |
| Ms. Anna Kverneland | Vice President of Investor Relations | - |
Riesgo de Auditoría
2
Riesgo del Consejo
4
Riesgo de Compensación
6
Riesgo de Derechos del Accionista
9
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for WILYY, sourced from Markets Gazette.